nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—DRD5—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0255	0.0255	CbGpPWpGaD
Methotrimeprazine—DRD4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0237	0.0237	CbGpPWpGaD
Methotrimeprazine—CHRM4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0234	0.0234	CbGpPWpGaD
Methotrimeprazine—DRD3—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.021	0.021	CbGpPWpGaD
Methotrimeprazine—DRD5—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0194	0.0194	CbGpPWpGaD
Methotrimeprazine—ADRA2B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.019	0.019	CbGpPWpGaD
Methotrimeprazine—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0188	0.0188	CbGpPWpGaD
Methotrimeprazine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0186	0.0186	CbGpPWpGaD
Methotrimeprazine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0178	0.0178	CbGpPWpGaD
Methotrimeprazine—ADRA2C—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0177	0.0177	CbGpPWpGaD
Methotrimeprazine—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.017	0.017	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0167	0.0167	CbGpPWpGaD
Methotrimeprazine—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0167	0.0167	CbGpPWpGaD
Methotrimeprazine—DRD2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0161	0.0161	CbGpPWpGaD
Methotrimeprazine—CHRM2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0156	0.0156	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0151	0.0151	CbGpPWpGaD
Methotrimeprazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0145	0.0145	CbGpPWpGaD
Methotrimeprazine—ADRA2A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0144	0.0144	CbGpPWpGaD
Methotrimeprazine—DRD4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0143	0.0143	CbGpPWpGaD
Methotrimeprazine—CHRM4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0139	0.0139	CbGpPWpGaD
Methotrimeprazine—CHRM5—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0135	0.0135	CbGpPWpGaD
Methotrimeprazine—DRD1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0129	0.0129	CbGpPWpGaD
Methotrimeprazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0128	0.0128	CbGpPWpGaD
Methotrimeprazine—DRD3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0127	0.0127	CbGpPWpGaD
Methotrimeprazine—ADRA1D—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0127	0.0127	CbGpPWpGaD
Methotrimeprazine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Methotrimeprazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Methotrimeprazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0125	0.0125	CbGpPWpGaD
Methotrimeprazine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0125	0.0125	CbGpPWpGaD
Methotrimeprazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0124	0.0124	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0123	0.0123	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0115	0.0115	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0115	0.0115	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.011	0.011	CbGpPWpGaD
Methotrimeprazine—DRD5—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.011	0.011	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0106	0.0106	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00997	0.00997	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00975	0.00975	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00959	0.00959	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00957	0.00957	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00954	0.00954	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00951	0.00951	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00942	0.00942	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00939	0.00939	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00872	0.00872	CbGpPWpGaD
Methotrimeprazine—DRD4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0081	0.0081	CbGpPWpGaD
Methotrimeprazine—CHRM4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00799	0.00799	CbGpPWpGaD
Methotrimeprazine—CHRM5—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00766	0.00766	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00736	0.00736	CbGpPWpGaD
Methotrimeprazine—DRD1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0073	0.0073	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00726	0.00726	CbGpPWpGaD
Methotrimeprazine—ADRA1D—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0072	0.0072	CbGpPWpGaD
Methotrimeprazine—DRD3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0072	0.0072	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00695	0.00695	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00662	0.00662	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00654	0.00654	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00654	0.00654	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0065	0.0065	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00624	0.00624	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00607	0.00607	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00597	0.00597	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0059	0.0059	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00589	0.00589	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00567	0.00567	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00551	0.00551	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00551	0.00551	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00543	0.00543	CbGpPWpGaD
Methotrimeprazine—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00542	0.00542	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00541	0.00541	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00539	0.00539	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00537	0.00537	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00532	0.00532	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00531	0.00531	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.005	0.005	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00493	0.00493	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00492	0.00492	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00491	0.00491	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0049	0.0049	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00488	0.00488	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00483	0.00483	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00482	0.00482	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00448	0.00448	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00435	0.00435	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00429	0.00429	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00411	0.00411	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00391	0.00391	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CXCL11—nasal cavity cancer	0.00386	0.00386	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00386	0.00386	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00349	0.00349	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—FRS2—nasal cavity cancer	0.00347	0.00347	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00335	0.00335	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00295	0.00295	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00291	0.00291	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CXCL11—nasal cavity cancer	0.0029	0.0029	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00289	0.00289	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00288	0.00288	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00285	0.00285	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00285	0.00285	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00265	0.00265	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—FRS2—nasal cavity cancer	0.00256	0.00256	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—FRS2—nasal cavity cancer	0.00253	0.00253	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—FRS2—nasal cavity cancer	0.00242	0.00242	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—FRS2—nasal cavity cancer	0.00228	0.00228	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—FRS2—nasal cavity cancer	0.00228	0.00228	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00205	0.00205	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00197	0.00197	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00192	0.00192	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00189	0.00189	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—FRS2—nasal cavity cancer	0.00174	0.00174	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—FRS2—nasal cavity cancer	0.00168	0.00168	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00168	0.00168	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00156	0.00156	CbGpPWpGaD
